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 One-Year Safety and Effi  cacy Study of Arformoterol 
Tartrate in Patients With Moderate to Severe COPD 
 James F.  Donohue ,  MD ,  FCCP ;  Nicola A.  Hanania ,  MD ,  FCCP ;  Barry  Make ,  MD ,  FCCP ;  Matthew C.  Miles ,  MD ; 
 Donald A.  Mahler ,  MD ;  Lisa  Curry ,  BS ;  Robert  Tosiello ,  MS ;  Alistair  Wheeler ,  MD ; and  Donald P.  Tashkin ,  MD 
 BACKGROUND:  Arformoterol tartrate (arformoterol, 15  m g bid) is a nebulized long-acting 
 b 2 -agonist approved for maintenance treatment of COPD. 
 METHODS:  Th is was a multicenter, double-blind, randomized, placebo-controlled study. Patients 
(aged   40 years with baseline FEV 1   65% predicted, FEV 1  . 0.50 L, FEV 1 /FVC   70%, 
and   15 pack-year smoking history) received arformoterol (n  5 420) or placebo (n  5 421) 
for 1 year. Th e primary assessment was time from randomization to respiratory death or fi rst 
COPD exacerbation-related hospitalization. 
 RESULTS:  Among 841 patients randomized, 103 had   1 primary event (9.5% vs 15.0%, for 
arformoterol vs placebo, respectively). Patients who discontinued treatment for any reason 
(39.3% vs 49.9%, for arformoterol vs placebo, respectively) were followed for up to 1 year post-
randomization to assess for primary events. Fewer patients receiving arformoterol than pla-
cebo experienced COPD exacerbation-related hospitalizations (9.0% vs 14.3%, respectively). 
Twelve patients (2.9%) receiving arformoterol and 10 patients (2.4%) receiving placebo died 
during the study. Risk for fi rst respiratory serious adverse event was 50% lower with arfor-
moterol than placebo ( P  5 .003). Numerically more patients on arformoterol (13; 3.1%) than 
placebo (10; 2.4%) experienced cardiac serious adverse events; however, time-to-fi rst cardiac 
serious adverse event was not signifi cantly diff erent. Improvements in trough FEV 1 and FVC 
were greater with arformoterol (least-squares mean change from baseline vs placebo: 0.051 L, 
 P  5 .030 and 0.075 L,  P  5 .018, respectively). Signifi cant improvements in quality of life (over-
all St. George’s Hospital Respiratory Questionnaire and Clinical COPD Questionnaire) were 
observed with arformoterol vs placebo ( P  , .05). 
 CONCLUSIONS:  Arformoterol demonstrated an approximately 40% lower risk of respiratory 
death or COPD exacerbation-related hospitalization over 1 year vs placebo. Arformoterol was 
well-tolerated and improved lung function vs placebo. 
 TRIAL REGISTRY:  ClinicalTrials.gov; No.: NCT00909779; URL: www.clinicaltrials.gov 
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 ABBREVIATIONS: AE  5 adverse event; HR  5 hazard ratio; IC  5 inspira-
tory capacity; LABA  5 long-acting  b -agonist; LSM  5 least-squares mean; 
MMRC  5 Modifi ed Medical Research Council; QoL  5 quality of life; 
RCI  5 repeated CI; SAE  5 serious adverse event; TORCH  5 Towards 
a Revolution in COPD Health  
 AFFILIATIONS: From the Department of Pulmonary Diseases and Crit-
ical Care Medicine (Dr Donohue), Th e University of North Carolina at 
Chapel Hill, Chapel Hill, NC; the Section of Pulmonary, Critical Care, and 
Sleep Medicine (Dr Hanania), Baylor College of Medicine, Houston, TX; 
the Division of Pulmonary, Critical Care, and Sleep Medicine (Dr Make), 
National Jewish Health, University of Colorado Denver School of 
Medicine, Denver, CO; the Department of Pulmonary, Critical Care, 
Allergy, and Immunologic Medicine (Dr Miles), Wake Forest School 
of Medicine, Winston-Salem, NC; the Department of Medicine 
(Dr Mahler), Geisel School of Medicine at Dartmouth, Hanover, NH; 
the Research & Development Division (Ms Curry, Mr Tosiello, and 
Dr Wheeler), Sunovion Pharmaceuticals Inc, Marlborough, MA; and 
the Department of Medicine/Division of Pulmonary and Critical 
Care Medicine (Dr Tashkin), David Geff en School of Medicine at UCLA, 
Los Angeles, CA. 
 Portions of the data were presented in abstract form at the American 
Th oracic Society Annual Meeting, May 17-22, 2013, Philadelphia, PA 
Open access under CC BY-NC-ND license.
 1532  Original Research  [   1 4 6  #  6   C H E S T   D E C E M B E R   2 0 1 4   ] 
 COPD is a common, preventable lung disease with 
treatable symptoms. 1 Airfl ow limitation is generally 
progressive and is partially reversible in most patients. 2,3 
Chronic airway and lung infl ammation contributes to 
progressive loss of lung function in aff ected individuals. 
Worldwide, COPD exacerbations and comorbidities are 
a major cause of morbidity and mortality, and are asso-
ciated with a high economic and social burden. 1,4,5 
 Inadequate diagnosis and treatment of COPD are 
common, 6,7 and may contribute to increased dyspnea, 
frequent exacerbations, deterioration of lung and physical 
function, and reduced quality of life (QoL). 1,8 Major 
goals of COPD treatment include reducing symptoms, 
improving QoL, limiting exacerbations, and slowing loss 
of lung function. 1 Depending on disease severity, patients 
typically experience one to three exacerbations yearly 9 ; 
however, exacerbation prevalence may be substantially 
higher. 10,11 Mortality (all-cause, lower respiratory, and 
cardiac) is higher among patients hospitalized for exacer-
bations. 12 Comorbidities associated with worse prognosis 
and lower QoL include cardiovascular disease, osteopo-
rosis, anxiety/depression, lung cancer, infections, metabolic 
syndrome, and diabetes. 1 
 Long-acting bronchodilators may reverse airway hyper-
reactivity and bronchospasm in patients with asthma or 
COPD. Among bronchodilators, long-acting  b -agonists 
(LABAs) have been associated with increased risk for 
exacerbation or death in patients with asthma 13-15 but 
not in patients with COPD, 16,17 nor has LABA use been 
associated with undue risk of adverse events (AEs) in 
COPD. A review of 20 studies (N  . 8,700) reported a 
low incidence of AEs and no association between LABA 
use and death, increased exacerbations, or COPD-related 
AEs. 16 A history of cardiovascular disease is common in 
patients with COPD 18 ; however, studies indicate compa-
rable or somewhat lower rates of AEs, including cardiac 
AEs, with LABAs compared with placebo. 19-21 One excep-
tion is the potential for cardiac arrhythmias in elderly 
patients with cardiovascular disease. 22 Th e US Food and 
Drug Administration has asked manufacturers of LABAs 
indicated for COPD to evaluate risks in this patient pop-
ulation. Th is trial was conducted as a postapproval com-
mitment to further evaluate the safety of arformoterol, 
especially the risk of life-threatening respiratory events, 
such as COPD exacerbations and respiratory death, over 
1 year in patients with moderate to severe COPD. 
Arformoterol tartrate (arformoterol) is a selective LABA 
administered via nebulization that is approved in the 
United States for maintenance treatment of broncho-
constriction in patients with COPD. 23 Th ese fi ndings 
may provide clinicians with additional assurance of 
arformoterol safety and effi  cacy in patients with 
moderate to severe COPD. 
 Materials and Methods 
 Patients 
 Patients were   40 years of age with COPD, a   15-pack-year smoking 
history, and baseline Modified Medical Research Council (MMRC) 
Dyspnea Scale Score   2. Prebronchodilator FEV 1 of   65% of pre-
dicted, FEV 1  . 0.50 L, and FEV 1 /FVC ratio of   70% were also required. 
(Donohue JF, Hanania NA, Make B, Curry L.  Am J Respir Crit Care 
Med . 2013;187:A39978; Hanania NA, Donohue JF, Make B.  Am J Respir 
Crit Care Med . 2013;187:A40227; and Make B, Hanania NA, Donohue JF. 
 Am J Respir Crit Care Med . 2013;187:A40252) and at CHEST 2013, 
October 26-31, 2013, Chicago, IL (Donohue JF, Hanania NA, Make B. 
 Chest . 2013;144[4_MeetingAbstracts]:714A and Hanania NA, Donohue JF, 
Make B.  Chest . 2013;144[4_MeetingAbstracts]:735A). 
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Patients were excluded for history of asthma (unless limited to child-
hood), life-threatening/unstable respiratory status including respiratory 
infection   30 days before screening, change in COPD medications 
  2 weeks before screening, or signs of infection   72 h before screening. 
An independent data and safety monitoring board monitored the study 
on an ongoing basis. Th e study was conducted in accordance with the 
Declaration of Helsinki and good clinical practice guidelines. Central/
local institutional review boards approved the protocol, and written 
informed consent was obtained from all patients. Additional information 
on the study and patients is available in  e-Appendix 1 .  
 Study Design and Treatment 
 Th is was a multicenter, double-blind, randomized, placebo-controlled, 
parallel-group, outpatient study conducted at 71 clinical sites in the 
United States. Patients with moderate to severe COPD were random-
ized 1:1 to arformoterol or placebo (citrate-buff ered saline), each admin-
istered bid via nebulization ( Fig 1 ). Participation consisted of six visits 
over about 1 year ( Fig 2 ). All patients were to be followed for 1 year 
postrandomization. Maintenance COPD medications other than LABAs 
were continued throughout the study and patients were permitted res-
cue albuterol (Ventolin HFA) and supplemental ipratropium use   6 h 
before visits. Disallowed medications and withholding periods for 
other long-acting bronchodilators (including tiotropium) are reported 
in  e-Table 1 . 
 Assessments 
 Th e primary end point of this event-driven study was time from ran-
domization to respiratory death or first COPD exacerbation-related 
hospitalization. Respiratory deaths were recorded when respiratory 
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 Figure 1 – Consolidated Standards 
of Reporting Trials (CONSORT) 
diagram. ITT  5 intent to treat. 
 Figure 2 – Study design. 
ARF15BID  5 arformoterol tartrate 
15  m g bid. 
status was the primary or contributing cause of death determined by the 
principal investigator/medical monitor. Secondary end points included 
protocol-defi ned COPD exacerbations, mortality, AEs, and serious AEs 
(SAEs). Cardiac deaths were attributed similarly to respiratory deaths. 
Effi  cacy assessments included change from baseline in spirometry and 
QoL measures (permission was obtained for use of the St. George’s 
Respiratory Questionnaire [SGRQ]). Patients who discontinued study 
treatment were followed by phone for primary events for 1 year post-
randomization ( e-Appendix 1 ).  
 Statistical Methodology 
 Th e statistical design was based on demonstrating noninferiority, defi ned 
as a   40% higher risk (hazard ratio [HR] 1.4) of a primary event with 
arformoterol vs placebo. The study was powered under a one-sided 
alternative hypothesis, in which arformoterol was superior to placebo 
(HR   0.80). Th e HR (90% CI) for the primary assessment was estimated 
using a Cox proportional hazards regression model, with treatment 
group, baseline smoking status, sex, age, BMI, and baseline FEV 1 as covari-
ates. Other assessments are summarized descriptively ( e-Appendix 1 ).  
 Results 
 Patients 
 Patient demographics and baseline characteristics, 
including smoking status, MMRC dyspnea status, 
frequency of exacerbations, comorbid conditions, and 
types and frequency of medications used were evenly 
balanced between treatment groups ( Table 1 ). 
 Disposition:  Overall, 45% of patients discontinued early 
from arformoterol (39.3%) or placebo (49.9%) treatment 
( Fig 1 ). Among those who discontinued, the majority 
discontinued arformoterol (51.5%) or placebo (60%) 
during the fi rst 3 months of treatment. Most discontinu-
ations (19.0% and 27.6%, respectively) were based on 
patient decision (individual reasons not reported). Dis-
continuations because of an AE were reported by 13.1% 
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 TABLE 1 ] Demographics and Baseline Characteristics (ITT Population) 
Characteristics Placebo (n  5 421) ARF15BID (n  5 420) All Patients (N  5 841)
Age, mean (SD), y 63.3 (9.5) 64.2 (9.3) 63.8 (9.4)
Sex, No. (%)
 Male 243 (57.7) 236 (56.2) 479 (57.0)
 Female 178 (42.3) 183 (43.6) 361 (42.9)
Race, No. (%)
 White 374 (88.8) 372 (88.6) 746 (88.7)
 Black 43 (10.2) 45 (10.7) 88 (10.5)
 Asian 2 (0.5) 2 (0.5) 4 (0.5)
 American Indian/Alaskan 1 (0.2) 1 (0.2) 2 (0.2)
 Other 1 (0.2) 0 1 (0.1)
Ethnicity, No. (%)
 Hispanic/Latino 15 (3.6) 9 (2.1) 24 (2.9)
 Non-Hispanic/Latino 402 (95.5) 411 (97.9) 813 (96.7)
 Not reported/unknown 4 (1.0) 0 4 (0.5)
COPD exacerbations in last year, mean (SD) 0.8 (1.1) 1.0 (1.4) a 0.9 (1.3) b 
Baseline COPD symptoms, No. (%)
 Coughing 320 (76.0) 321 (76.4) 641 (76.2)
 Wheezing 303 (72.0) 298 (71.0) 601 (71.5)
 Bringing up mucus 289 (68.6) 283 (67.4) 572 (68.0)
 Chest tightness 199 (47.3) 195 (46.4) 394 (46.8)
 Shortness of breath 391 (92.9) 395 (94.0) 786 (93.5)
 Other 17 (4.0) 23 (5.5) 40 (4.8)
 None 6 (1.4) 6 (1.4) 12 (1.4)
MMRC Dyspnea Scale score, mean (%) c 
 2 101 (24.0) 95 (22.6) 196 (23.3)
 3 224 (53.2) 220 (52.4) 444 (52.8)
 4 96 (22.8) 105 (25.0) 201 (23.9)
% Predicted FEV 1 , mean (SD) 39.4 (13.9) d 39.7 (13.2) 39.5 (13.5) e 
Baseline smoking status, No. (%)
 Current 218 (51.8) 214 (51.0) 432 (51.4)
 Former 203 (48.2) 206 (49.0) 409 (48.6)
No. of current packs per day, No. (%) f 
 0 203 (48.2) 206 (49.0) 409 (48.6)
  . 0-1 159 (37.8) 145 (34.5) 304 (36.1)
  . 1-2 50 (11.9) 60 (14.3) 110 (13.1)
  . 2-4 7 (1.7) 6 (1.4) 13 (1.5)
No. of pack-y smoked, No. (%)
   15- , 25 41 (9.7) 40 (9.5) 81 (9.6)
   25- , 30 36 (8.6) 29 (6.9) 65 (7.7)
   30 344 (81.7) 351 (83.6) 695 (82.6)
Comorbidities, No. (%)
 Respiratory
  Pneumonia 62 (14.7) 61 (14.5) 123 (14.6)
(Continued)
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Characteristics Placebo (n  5 421) ARF15BID (n  5 420) All Patients (N  5 841)
 Cardiovascular
  Hypertension 240 (57.0) 253 (60.2) 493 (58.6)
  Hyperlipidemia 88 (20.9) 94 (22.4) 182 (21.6)
  Hypercholesterolemia 87 (20.7) 87 (20.7) 174 (20.7)
  Coronary artery disease 55 (13.1) 49 (11.7) 104 (12.4)
  Myocardial infarction 38 (9.0) 31 (7.4) 69 (8.2)
 Metabolic
  GERD 126 (29.9) 146 (34.8) 272 (32.3)
  T2DM 44 (10.5) 45 (10.7) 89 (10.6)
 Psychologic disorders
  Depression 111 (26.4) 106 (25.2) 217 (25.8)
  Anxiety 94 (22.3) 83 (19.8) 177 (21.0)
  Insomnia 82 (19.5) 81 (19.3) 163 (19.4)
  Sleep apnea syndrome 51 (12.1) 54 (12.9) 105 (12.5)
Concomitant medications   20% of patients, No. (%)
 Respiratory
  Glucocorticoids 238 (56.8) 241 (57.4) 479 (57.0)
  Anticholinergics 206 (49.8) 225 (53.6) 431 (51.2)
  Selective  b 2  adrenoreceptor agonists g 113 (26.8) 112 (26.7) 225 (26.8)
  Other, such as supplemental oxygen 106 (25.2) 99 (23.6) 205 (24.4)
 Other comorbidity
  Platelet aggregation inhibitors 150 (35.6) 152 (36.2) 302 (35.9)
  HMG COA reductase inhibitors 151 (35.9) 150 (35.7) 301 (35.8)
  Proton pump inhibitors 89 (21.1) 115 (27.4) 204 (24.3)
  ACE inhibitors 91 (21.6) 108 (25.7) 199 (23.7)
  Propionic acid derivatives 77 (18.3) 98 (23.3) 175 (20.8)
 All patients randomized received at least one dose of study medication and comprised the ITT population. ACE  5 angiotensin-converting enzyme; 
ARF15BID  5 arformoterol tartrate 15  m g bid; GERD  5 gastroesophageal reﬂ ux disease; HMG COA  5 hydroxymethyl glutaryl coenzyme A; ITT  5 intent to 
treat; MMRC  5 Modiﬁ ed Medical Research Council; T2DM  5 type 2 diabetes mellitus. 
 a No.  5 418. 
 b No.  5 839. 
 c Scores on the MMRC Dyspnea Questionnaire ranged from 0 to 4, with a score of 4 indicating that a patient was too breathless to leave the house or 
became breathless when dressing or undressing. The highest numbered question to which the patient answered “Yes” was the Dyspnea Scale Score. 
No patients had MMRC scores of 0 or 1; therefore, these values are omitted. 
 d No.  5 420. 
 e No.  5 840. 
 f No patients reported smoking more than four packs/d. 
 g Data on selective  b 2  adrenoreceptor agonist use represent patient concomitant medications at baseline and before visit 2, when minimum washout 
periods and exclusion for study duration began. 
TABLE 1 ] (continued)
and 12.6% of patients, respectively. Th e most frequently 
reported AE resulting in discontinuation was COPD 
exacerbation in 4.5% and 6.4%, respectively. 
 Safety 
 Respiratory Deaths and COPD Exacerbation-Related 
Hospitalizations:  Primary events were reported in 
40 patients (9.5%) and 63 patients (15.0%) receiving 
arformoterol or placebo, respectively; most experienced 
a single event ( Fig 3 ,  Table 2 ). Time to respiratory death 
or fi rst COPD exacerbation-related hospitalization was 
171.7 days and 155 days, respectively, for patients having 
a primary event. Respiratory death was reported for fi ve 
patients (1.2%) and eight patients (1.9%), respectively, and 
COPD exacerbation-related hospitalizations were reported 
for 38 patients (9.0%) and 60 patients (14.3%), respectively. 
Of note, patients experiencing COPD exacerbation-
related hospitalizations could remain on study. 
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 Sensitivity Analyses of the Primary End Point:  Th e 
point estimate for the primary event indicated an approx-
imately 40% reduction in risk with arformoterol vs placebo 
(HR, 0.606; 90% repeated CI [RCI], 0.425, 0.864) ( Fig 4 , 
 Table 2 ). Sensitivity analyses were conducted to assess 
the eff ect of events recorded during the follow-up period 
after early treatment termination. Results were con-
sistent for all sensitivity analyses ( e-Appendix 1 ,  Fig 4 ).  
 Protocol-Defined COPD Exacerbations:  Protocol-
defined COPD exacerbations (ie, increased COPD 
symptoms that necessitated any change in baseline 
medication) were reported by 122 patients (29%) 
receiving arformoterol and 132 patients (31.4%) receiving 
placebo. Approximately 17% of patients in each group 
reported one event; 6.9% and 8.1% of patients, respec-
tively, reported two events; and 5.2% and 6.2%, respec-
tively, reported at least three events. Risks for first 
protocol-defined COPD exacerbation (HR, 0.801; 
 P  5 .078) and recurrent protocol-defi ned COPD exacer-
bation (HR, 0.768;  P  5 .043) were lower with arformoterol 
than placebo. 
 Adverse Events:  Patients receiving arformoterol or pla-
cebo had a similar incidence of AEs (72.9% vs 68.2%, 
respectively). Th e most frequently reported AE was an 
exacerbation or worsening of COPD (not protocol-
defined), which was less commonly reported with 
arformoterol than placebo (23.3% vs 28.0% patients, 
respectively). Th e only nonrespiratory AEs occurring in 
  5% of patients were headache, nausea, and urinary 
tract infection ( Table 3 ). Additional information on 
treatment-related AEs is available in  e-Appendix 1 . 
 Deaths:  Twelve patients (2.9%) receiving arformoterol 
and 10 patients (2.4%) receiving placebo died postran-
domization. In the arformoterol group, two deaths were 
attributed to dual SAEs (cardiorespiratory arrest and 
squamous cell carcinoma in one patient; pneumonia 
and respiratory arrest in one patient). Additionally, 
two deaths were attributed to myocardial infarction and 
one each to COPD, cardiorespiratory arrest, respiratory 
failure, coronary artery disease, squamous cell carcinoma, 
brain neoplasia, head injury, and sepsis. Seven patients 
receiving placebo died of COPD, and one each from 
pneumonia, congestive heart failure, and lung cancer. 
 Figure 3 – Kaplan-Meier plot of the 
cumulative probability of events for 
time to respiratory death or fi rst 
COPD exacerbation-related hospi-
talization (ITT population). See 
 Figure 1 and 2 legends for expansion 
of abbreviations. 
 TABLE 2 ]  Time to Respiratory Death a or First COPD 
Exacerbation-Related Hospitalization b 




(n  5 421)
ARF15BID 
(n  5 420)
No. of primary events 88 54
 No. of patients with 
 primary events (%)
63 (15.0) 40 (9.5)
No. of patients with 
 respiratory death (%) a 
8 (1.9) 5 (1.2)
No. of patients with COPD 
  exacerbation-related 
hospitalizations (%) b 
60 (14.3) 38 (9.0)
 1 event 45 (10.7) 31 (7.4)
 2 events 8 (1.9) 4 (1.0)
   3 events 7 (1.7) 3 (0.7)
Time-to-¿ rst primary 
  event for those with 
an event, d (SD)
155.0 (91.2) 171.7 (98.7)
Hazard ratio for time to 
 primary event c 
0.606
 Adjusted 90% RCI d 0.425, 0.864
 RCI  5 repeated CI. See  Table 1 legend for expansion of other 
abbreviations. 
 a Respiratory deaths were deﬁ ned as having a probable cause related to 
respiratory pathophysiology. 
 b A COPD exacerbation-related hospitalization was deﬁ ned as hospitalization 
(any inpatient admission or ED visit lasting  . 24 h, including hospice) in 
which the reason for admission was COPD exacerbation or in which a 
COPD exacerbation preceded, or occurred concomitantly with, the onset of 
the event for which the patient was hospitalized. 
 c Estimated from a Cox proportional hazards model with treatment 
group, baseline smoking status, sex, age, BMI, and baseline FEV 1 as 
covariates. 
 d RCI was adjusted for planned interim analysis. 
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 Figure 4 – Primary and sensitivity 
analyses for time-to-fi rst-event 
analysis: hazard ratio and 90% 
repeated CI (ITT population). 
Hazard ratios are indicated by  3 ; 
 represents the bounds of the CIs. 
IPD  5 important protocol deviation. 
See  Figure 1 and 2 legends for 
expansion of other abbreviations. 
 TABLE 3 ]  Most Frequently Reported AEs (  5% of Patients in Either Treatment Group by Individual Category) 
by Preferred Term (ITT Population) 
System Organ Class/ Preferred Term
Placebo (n  5 421) ARF15BID (n  5 420)
Patients, No. (%) Events, No. Patients, No. (%) Events, No.
Any AE 287 (68.2) 1,205 306 (72.9) 1,321
Respiratory, thoracic, and mediastinal disorders 167 (39.7) 348 156 (37.1) 313
 COPD a 118 (28.0) 198 98 (23.3) 159
 Dyspnea 30 (7.1) 46 24 (5.7) 27
Infections and infestations 146 (34.7) 270 163 (38.8) 310
 Bronchitis 34 (8.1) 46 44 (10.5) 62
 Nasopharyngitis 33 (7.8) 49 38 (9.0) 50
 Sinusitis 22 (5.2) 29 19 (4.5) 27
 Upper respiratory tract infection 22 (5.2) 26 22 (5.2) 28
 Urinary tract infection 21 (5.0) 23 17 (4.0) 21
GI disorders 64 (15.2) 105 79 (18.8) 121
 Nausea 14 (3.3) 18 21 (5.0) 25
Nervous system disorders 42 (10.0) 71 69 (16.4) 104
 Headache 21 (5.0) 39 36 (8.6) 54
 AEs were deﬁ ned as events with onset date occurring on or after the date of ﬁ rst dose of double-blind study medication. AE  5 adverse event. See 
 Table 1 legend for expansion of other abbreviations. 
 a The verbatim terms of COPD exacerbation, acute COPD, exacerbation of severe COPD, COPD exacerbation with hospitalization, worsening of COPD, 
and end-stage COPD were coded to COPD. 
 Serious Adverse Events:  Eighty-six patients (20.5%) 
and 95 patients (22.6%) receiving arformoterol or 
placebo, respectively, experienced SAEs ( Table 4 ). Th e 
most frequently reported SAE was COPD exacerba-
tion in 8.3% and 13.1% of patients, respectively. SAEs 
reported in   2% of patients receiving arformoterol and 
patients receiving placebo, respectively, included respi-
ratory, thoracic, and mediastinal disorders (8.3% 
vs 14.7%), infections and infestations (5.2% vs 6.4%), 
cardiac disorders (3.1% vs 2.4%), and GI disorders 
(2.1% vs 2.4%). 
 Analysis of Time-to-First SAE:  Time-to-event analyses 
(defi ned as the time from randomization until the fi rst 
event onset date) were conducted for fi rst SAE, respira-
tory SAE, cardiac SAE, and AE resulting in discontinua-
tion of study treatment. Risk for a fi rst respiratory SAE 
was about 50% lower with arformoterol than placebo 
(HR, 0.508;  P  5 .003). Time-to-fi rst SAE and time-to-
fi rst AE resulting in discontinuation were numerically 
longer, whereas time-to-fi rst cardiac SAE was numeri-
cally shorter with arformoterol than placebo. No statis-
tically signifi cant treatment diff erences were observed 
( e-Appendix 1 ,  Table 5 ).  
 Results of clinical assessments, including laboratory 
fi ndings, vital signs, and ECG results are described in 
 e-Appendix 1 . 
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 Eﬃ  cacy 
 Lung Function:  Arformoterol demonstrated greater 
improvements from baseline in lung function at 1 year 
vs placebo ( Table 6 ). Arformoterol signifi cantly improved 
trough FEV 1 from baseline (least-squares mean [LSM] 
diff erence vs placebo: 0.051 L;  P  5 .030). Similarly, 
arformoterol signifi cantly improved % predicted FEV 1 
from baseline (LSM diff erence, 1.448;  P  5 .039) and 
trough FVC from baseline (LSM diff erence, 0.075 L; 
 P  5 .018), whereas change in trough inspiratory capacity 
 TABLE 4 ]  Most Frequently Reported SAEs (  1% of Patients in Either Treatment Group by Individual 
Category) by Preferred Term (ITT Population) 
System Organ Class/Preferred Term
Placebo (n  5 421) ARF15BID (n  5 420)
Patients, No. (%) Events, No. Patients, No. (%) Events, No.
Any SAE 95 (22.6) 200 86 (20.5) 154
Respiratory, thoracic, and mediastinal disorders 62 (14.7) 93 35 (8.3) 51
 Acute respiratory failure 4 (1.0) 5 1 (0.2) 1
 COPD 55 (13.1) 76 35 (8.3) 44
Infections and infestations 27 (6.4) 35 22 (5.2) 29
 Bronchitis 9 (2.1) 10 3 (0.7) 4
 Pneumonia 14 (3.3) 18 12 (2.9) 13
 SAEs were deﬁ ned as events with onset date occurring on or after the date of ﬁ rst dose of double-blind study medication. Reports of SAEs were 
collected from the time of informed consent to 30 d after last scheduled dose. For patients who discontinued treatment before completing the study, 
primary events and other fatal events were collected up to 1 y after randomization. SAE  5 serious adverse event. See  Table 1 legend for expansion of 
other abbreviations. 
 TABLE 5 ]  Analyses of Time-to-First SAE (ITT population) 
Analyses Placebo (n  5 421) ARF15BID (n  5 420)
Time-to-¿ rst SAE
 Patients with   1 SAE, No. (%) a 81 (19.2) 80 (19.0)
 Mean (SD) days until ¿ rst SAE 144.0 (98.1) 167.9 (108.3)
 Hazard ratio (95% CI) b ... 0.814 (0.597, 1.111)
 Wald test  P value ... .194
Time-to-¿ rst respiratory SAE
 Patients with   1 respiratory SAE, No. (%) a 51 (12.1) 32 (7.6)
 Mean (SD) days until ¿ rst respiratory SAE 146.2 (100.1) 164.8 (88.8)
 Hazard ratio (95% CI) b ... 0.508 (0.326, 0.793)
 Wald test  P value ... .003
Time-to-¿ rst cardiac SAE
 Patients with   1 cardiac SAE, No. (%) a 8 (1.9) 10 (2.4)
 Mean (SD) days until ¿ rst cardiac SAE 164.9 (160.0) 140.1 (73.6)
 Hazard ratio (95% CI) b ... 1.059 (0.415, 2.700)
 Wald test  P value ... .905
Time-to-¿ rst AE resulting in discontinuation
 Patients with   1 AE resulting in discontinuation, No. (%) a 50 (11.9) 50 (11.9)
 Mean (SD) days until ¿ rst AE 88.8 (100.1) 112.8 (104.0)
 Hazard ratio (95% CI) b ... 0.881 (0.594, 1.307)
 Wald test  P value ... .530
 See  Table 1, 3, and 4 legends for expansion of abbreviations.  
 a Twenty patients (14 placebo and six arformoterol) experienced a ﬁ rst SAE after treatment discontinuation  1 30 d (while still being monitored) and 
were censored in the time-to-ﬁ rst SAE analysis; therefore, n  5 81 and n  5 80 patients in the placebo and arformoterol arms, respectively. 
 b Hazard ratio, 95% CI for the hazard ratio, and Wald test  P value were from a Cox proportional hazards regression model for time-to-ﬁ rst event with 
treatment group, baseline smoking status, sex, age, and baseline FEV 1 values as covariates. 
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(IC) from baseline was not significantly greater with 
arformoterol (LSM diff erence, 0.045 L;  P  5 .125). Abso-
lute mean values for change in FEV 1 were comparable 
to LSM values reported herein. See  e-Appendix 1 and 
e-Table 2 for QoL assessments and rescue medication 
use. 
 Discussion 
 Th e primary objective of this phase 4 trial (ie, postap-
proval commitment) in patients with COPD was to 
determine whether long-term use of arformoterol was 
associated with fatal and life-threatening respiratory 
 TABLE 6 ]  Ef¿ cacy Outcomes Following Study 
Treatment of 1 Year (ITT Population) 
Outcomes
Placebo 
(n  5 421)
ARF15BID 
(n  5 420)
Trough FEV 1 , L a 
 Baseline, mean (SD) 1.178 (0.487) 1.176 (0.482)
 LSM change from 
 baseline (SE)
0.033 (0.017) 0.084 (0.016)
 LSM difference vs 
 placebo (95% CI)
0.051 (0.005, 0.097)
 P value b .030
% Predicted FEV 1 a 
 Baseline, mean (SD) 39.4 (13.9) 39.7 (13.2)
 LSM change from 
 baseline (SE)
1.866 (0.514) 3.313 (0.475)
 LSM difference vs 
 placebo (95% CI)
1.448 (0.074, 2.822)
 P value b .039
Trough FVC, L a 
 Baseline, mean (SD) 2.400 (0.813) 2.396 (0.795)
 LSM mean change 
 from baseline (SE)
0.046 (0.023) 0.121 (0.022)
 LSM difference vs 
 placebo (95% CI)
0.075 (0.013, 0.138)
 P value b .018
Trough IC, L c 
 Baseline, mean (SD) 1.938 (0.658) 1.894 (0.647)
 LSM mean change 
 from baseline (SE)
0.017 (0.022) 0.063 (0.020)
 LSM difference vs 
 placebo (95% CI)
0.045 (–0.013, 0.103)
 P value b .125
 IC  5 inspiratory capacity; LSM  5 least squares mean. See  Table 1 legend 
for expansion of other abbreviations. 
 a n  5 420 at baseline and overall. 
 b Overall treatment eﬀ ect from the repeated measures linear model for 
change from baseline with covariates for treatment, baseline smoking 
status, baseline IC, baseline IC-by-visit interaction, visit, and the 
treatment-by-visit interaction.  P values were unadjusted for multiplicity. 
 c n  5 416 at baseline and overall. 
events, which had been observed in studies of LABA-
containing products in patients with asthma. 14,15,24 In 
this study, arformoterol demonstrated an approxi-
mately 40% lower risk of respiratory death or COPD 
exacerbation-related hospitalization over 1 year vs placebo, 
suggesting that, in this study population, no such associa-
tion was detected. Patients receiving arformoterol experi-
enced fewer protocol-defi ned COPD exacerbations, 
fewer respiratory SAEs, and a signifi cantly lower risk 
(about 50%;  P  5 .003) of a fi rst respiratory SAE vs placebo. 
Cardiac SAEs were numerically higher with arformoterol 
than placebo (HR, 1.059;  P  5 .905). Arformoterol signifi -
cantly improved QoL measures (SGRQ total score, 
Symptoms and Impacts individual scores, and Clinical 
COPD Questionnaire [CCQ] score) ( e-Fig 1 ) from 
baseline vs placebo. Improvements in lung function 
(ie, mean placebo-adjusted increase in trough FEV 1 of 
51 mL) were consistent with those observed with other 
approved bronchodilators in a population with mostly 
severe airfl ow limitation who were receiving substantial 
background therapy. 25 Findings were consistent with 
previous studies demonstrating that arformoterol is an 
eff ective and tolerable COPD maintenance therapy, and 
no safety signal suggestive of drug-related, life-threatening 
respiratory or cardiac events was evident. 4,26-28 
 Th e safety and effi  cacy of LABAs and long-acting mus-
carinic antagonists in COPD have been demonstrated in 
several trials. Th e fi rst two trials were long-term “mega 
trials”—Understanding Potential Long-term Impacts on 
Function with Tiotropium (UPLIFT) (tiotropium) and 
Towards a Revolution in COPD Health (TORCH) 
(salmeterol/fl uticasone propionate combination). 29,30 
Although neither long-term trial achieved signifi cant 
primary outcomes (reduction in lung function decline 
over 4 years in UPLIFT or reduction in all-cause mor-
tality aft er 3 years in TORCH), they demonstrated that 
long-acting bronchodilators reduce exacerbation rates 
and improve health status and QoL with no increased 
mortality risk or an excess of cardiac SAEs. An addi-
tional trial of note assessed the eff ect of triple therapy 
(budesonide/formoterol plus tiotropium) over 12 weeks. 31 
Although this trial supports the administration of long-
acting bronchodilators in combination with inhaled 
corticosteroids (about 57% of current-study patients), 
its short duration does not permit defi nitive conclusions 
regarding long-term effi  cacy and safety. Th e current 
1-year study demonstrates the safety and effi  cacy of 
arformoterol and provides reassurance that LABAs do 
not increase the risk of exacerbations or respiratory 
death in patients with COPD. 
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 Study strengths include a large patient cohort with long-
term treatment data. Importantly, 1-year effi  cacy data 
for pulmonary function measures provide additional 
information on the eff ects of nebulized bronchodilator 
treatment against a background of naturally declining 
lung function. A noninferiority statistical design was 
used; however, arformoterol was superior to placebo 
based on an upper bound of the HR (90% RCI) point 
estimate of 0.606 (0.425, 0.864) being  , 1.0 (null value 
of no treatment diff erence). Sensitivity analyses assess-
ing the impact of treatment follow-up, important proto-
col deviations, and baseline covariates support the 
primary analysis that arformoterol did not increase the 
risk of respiratory death or COPD exacerbation-related 
hospitalizations vs placebo during 1 year of treatment. 
 Th ere were several study limitations. Th ere was a low 
baseline exacerbation rate of about one COPD exacer-
bation in the prior year (low-moderate risk). It is 
unclear what eff ect a lower baseline exacerbation rate 
would have on study outcomes. However, because 
sample size was driven by the number of primary events 
observed, the likely impact was only on the number of 
patients needed for enrollment. Other baseline charac-
teristics (including percent-predicted FEV 1 of about 
40%) indicate a population with fairly severe disease 
(based on GOLD [Global Initiative for Chronic 
Obstructive Lung Disease] guidelines in eff ect at study 
initiation). If patients in the current study were reassessed 
using the current GOLD evaluation criteria (eg, symp-
toms, exacerbation history, and exacerbation rates at 
baseline), one would expect a more complete picture of 
exacerbation risk, but not necessarily of mortality risk. 
Th ere were also a high number of patient withdrawals 
from treatment (but not withdrawals from study). Forty-
fi ve percent of patients discontinued arformoterol 
(39.3%) and placebo (49.9%) during the study; however, 
among 841 randomized patients, only 89 (10.6%; 
42 arformoterol, 47 placebo) were not followed for 1 year. 
Th e discontinuation rate is comparable to, albeit at the 
higher end of, the range observed in other long-term 
COPD studies (27%-44%). 28-30 Patient-initiated discon-
tinuation was more common with placebo than arfor-
moterol (a fi nding that may be related to lack of effi  cacy, 
as has been discussed previously 32 ), although this was 
not assessed as an independent reason for withdrawal. 
Discontinuations occurred primarily during the first 
3 months of treatment. 
 Th e eff ect of discontinuations on incidence of primary 
events was assessed in a sensitivity analysis ( e-Table 3 ). 
Specifi cally, how many events would need to occur in 
patients who discontinued vs patients who completed 
the trial to overturn the fi ndings for superiority and 
noninferiority of arformoterol? Th e incidence of the 
primary end point would have to be fi vefold higher 
(about 50% vs about 10%) in arformoterol dropouts 
than in completers to overturn the superiority fi nding, 
and  . 20-fold higher to overturn the noninferiority 
fi nding. We believe that this analysis provides reassur-
ance that the number of discontinuations postrandom-
ization in this study would not aff ect our conclusions. 
 In conclusion, this long-term safety study demonstrates 
that arformoterol did not increase the risk of respiratory 
death or COPD exacerbation-related hospitalizations 
vs placebo during 1 year of treatment. Th ese results are 
consistent with fi ndings in the 3-year TORCH study 
that demonstrated the long-term safety of LABAs in 
patients with COPD. 29 In addition, patients receiving 
arformoterol experienced improvements in lung func-
tion and QoL measures vs patients receiving placebo. 
 journal.publications.chestnet.org  1541 
 Acknowledgments 
 Author contributions:  J. F. D. takes fi nal 
responsibility for the content of this manu-
script, including the data and analysis. J. F. D., 
N. A. H., B. M., M. C. M., D. A. M., L. C., 
R. T., A. W., D. P. T. contributed to data 
analysis and interpretation, writing, critical 
review and revision, and final approval of 
the published version; N. A. H., B. M., and 
L. C. contributed to study conduct; L. C. and 
R. T. contributed to study design; and R. T. 
contributed to the plan on statistical analysis. 
 Financial/nonfi nancial disclosures: Th e 
authors have reported to  CHEST the 
following confl icts of interest: Dr Donohue is 
a consultant to and serves on the advisory 
committee for Sunovion Pharmaceuticals 
Inc. Dr Hanania is a consultant to Boehringer 
Ingelheim GmbH, GlaxoSmithKline plc, 
Mylan Inc, Novartis AG, Pearl Th erapeutics, 
Inc, Pfi zer Inc, and Sunovion Pharmaceuticals 
Inc, and provides institutional support for 
conduct of study to Sunovion Pharmaceuticals 
Inc. Dr Make is a consultant to and serves 
on the advisory committee for Sunovion 
Pharmaceuticals Inc; is a speaker/advisor for 
AstraZeneca, Boehringer Ingelheim GmbH, 
GlaxoSmithKline, Forest Laboratories Inc, 
Pfizer Inc, Respironics, Merck & Co Inc, 
Coviden, Aerocrine, and Th eravance; and 
has received grants from AstraZeneca, Forest 
Laboratories Inc, Sunovion Pharmaceuticals 
Inc, GlaxoSmithKline, Boehringer Ingelheim 
GmbH, Pfi zer Inc, and NABI. Dr Miles is a 
consultant to Sunovion Pharmaceuticals Inc. 
Dr Mahler is a consultant to, and provides 
institutional support for conduct of study to, 
Boehringer Ingelheim GmbH; is a consultant 
to and serves on the advisory committee for 
Forest Laboratories, Inc; is a consultant to, 
serves on the advisory committee for, and 
provides institutional support for conduct of 
study to GlaxoSmithKline plc; serves on the 
advisory committee for Merck & Co, Inc; is a 
consultant to, serves on the advisory commit-
tee for, and provides institutional support for 
conduct of study to Novartis AG; serves on 
the advisory committee for Pearl Th erapeutics, 
Inc; and is a consultant to, serves on the 
advisory committee for, and provides insti-
tutional support for conduct of study to 
Sunovion Pharmaceuticals Inc. Ms Curry, 
Mr Tosiello, and Dr Wheeler are employees 
of Sunovion Pharmaceuticals Inc. Dr Tashkin 
serves on the advisory committee and is a 
speaker for AstraZeneca; received a research 
grant from and is a speaker for Boehringer 
Ingelheim GmbH; is a speaker for Forest 
Laboratories, Inc; received a research grant from 
GlaxoSmithKline plc; serves on the advisory 
committee for, received a research grant from, 
and is a speaker for Novartis AG; received a 
research grant from Pearl Th erapeutics, Inc; 
received a research grant from and is a speaker 
for Pfi zer Inc; and serves on the advisory 
committee for and received a research grant 
from Sunovion Pharmaceuticals Inc. 
 Role of sponsors: Th e sponsor had no role in 
the design of the study, the collection and 
analysis of the data, or the preparation of the 
manuscript. 
 Other contributions:  We thank John 
O’Flaherty, PhD, of ProEd Communications 
Inc, a Healthcare Consultancy Group 
Company, for his medical editorial assistance 
with this manuscript. 
 Additional information: Th e e-Appendix, 
e-Figure, and e-Tables can be found in the 
Supplemental Materials section of the online 
article. 
 References 
  1 .  Global strategy for diagnosis, manage-
ment and prevention of COPD .  Global 
Initiative for Chronic Obstructive Lung 
Disease website.  http://www.goldcopd.org/ . 
Accessed October 2, 2013. 
  2 .  American Th oracic Society .  Standards for 
the diagnosis and care of patients with 
chronic obstructive pulmonary disease . 
 Am J Respir Crit Care Med .  1995 ; 
152 ( 5 pt 2 ): S77 - S121 . 
  3 .  Pauwels  RA ,  Buist  AS ,  Ma  P ,  Jenkins  CR , 
 Hurd  SS ;  GOLD Scientifi c Committee . 
 Global strategy for the diagnosis, man-
agement, and prevention of chronic 
obstructive pulmonary disease: National 
Heart, Lung, and Blood Institute and 
World Health Organization Global 
Initiative for Chronic Obstructive Lung 
Disease (GOLD): executive summary . 
 Respir Care .  2001 ; 46 ( 8 ): 798 - 825 . 
  4 .  Hanania  NA ,  Donohue  JF ,  Nelson  H ,  
et al .  Th e safety and effi  cacy of arfor-
moterol and formoterol in COPD .  COPD . 
 2010 ; 7 ( 1 ): 17 - 31 .  
  5 .  Tuder  RM ,  Petrache  I .  Pathogenesis of 
chronic obstructive pulmonary disease .  J 
Clin Invest .  2012 ; 122 ( 8 ): 2749 - 2755 .  
  6 .  van den Boom  G ,  van Schayck  CP ,  van 
Möllen  MP ,  et al .  Active detection of 
chronic obstructive pulmonary disease 
and asthma in the general population. 
Results and economic consequences of 
the DIMCA program .  Am J Respir Crit 
Care Med .  1998 ; 158 ( 6 ): 1730 - 1738 .  
  7 .  Ingebrigtsen  TS ,  Marott  JL ,  Vestbo  J , 
 et al .  Characteristics of undertreatment in 
COPD in the general population .  Chest . 
 2013 ; 144 ( 6 ): 1811 - 1818 .  
  8 .  Mathers  CD ,  Loncar  D .  Projections of 
global mortality and burden of disease 
from 2002 to 2030 .  PLoS Med .  2006 ; 3 ( 11 ): 
e442 .  
  9 .  Hurst  JR ,  Vestbo  J ,  Anzueto  A ,  et al ; 
 Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate Endpoints 
(ECLIPSE) Investigators .  Susceptibility 
to exacerbation in chronic obstruc-
tive pulmonary disease .  N Engl J Med . 
 2010 ; 363 ( 12 ): 1128 - 1138 .  
  10 .  Miravitlles  M ,  Mayordomo  C ,  Artés  M , 
 Sánchez-Agudo  L ,  Nicolau  F ,  Segú  JL . 
 Treatment of chronic obstructive pul-
monary disease and its exacerbations 
in general practice. EOLO Group. 
Estudio Observacional de la Limitación 
Obstructiva al Flujo aEreo .  Respir Med . 
 1999 ; 93 ( 3 ): 173 - 179 .  
  11 .  Seemungal  TA ,  Donaldson  GC ,  Paul  EA ,  
Bestall  JC ,  Jeff ries  DJ ,  Wedzicha  JA . 
 Eff ect of exacerbation on quality of life in 
patients with chronic obstructive pulmo-
nary disease .  Am J Respir Crit Care Med . 
 1998 ; 157 ( 5 pt 1 ): 1418 - 1422 .  
  12 .  Halpin  DM ,  Decramer  M ,  Celli  B , 
 Kesten  S ,  Liu  D ,  Tashkin  DP . 
 Exacerbation frequency and course of 
COPD .  Int J Chron Obstruct Pulmon Dis . 
 2012 ; 7 : 653 - 661 .  
  13 .  Seymour  SM ,  Sullivan  EJ ,  Chowdhury  BA , 
 Meyer  RJ ,  Davi  RC .  Comments on the 
Salmeterol Multicenter Asthma Research 
Trial .  Chest .  2006 ; 130 ( 3 ): 930 - 931 .  
  14 .  Chowdhury  BA ,  Dal Pan  G .  Th e FDA 
and safe use of long-acting beta-agonists 
in the treatment of asthma .  N Engl J Med . 
 2010 ; 362 ( 13 ): 1169 - 1171 .  
  15 .  Chowdhury  BA ,  Seymour  SM , 
 Levenson  MS .  Assessing the safety of 
adding LABAs to inhaled corticoste-
roids for treating asthma .  N Engl J Med . 
 2011 ; 364 ( 26 ): 2473 - 2475 .  
  16 .  Decramer  ML ,  Hanania  NA ,  Lötvall  JO ,  
Yawn  BP .  Th e safety of long-acting 
 b 2-agonists in the treatment of stable 
chronic obstructive pulmonary disease . 
 Int J Chron Obstruct Pulmon Dis . 
 2013 ; 8 : 53 - 64 .  
  17 .  Kew  KM ,  Mavergames  C ,  Walters  JA . 
 Long-acting beta2-agonists for chronic 
obstructive pulmonary disease .  Cochrane 
Database Syst Rev .  2013 ; 10 : CD010177 . 
  18 .  Feary  JR ,  Rodrigues  LC ,  Smith  CJ , 
 Hubbard  RB ,  Gibson  JE .  Prevalence of 
major comorbidities in subjects with 
COPD and incidence of myocardial 
infarction and stroke: a comprehensive 
analysis using data from primary care . 
 Th orax .  2010 ; 65 ( 11 ): 956 - 962 .  
  19 .  Calverley  PM ,  Anderson  JA ,  Celli  B ,  et al ; 
TORCH Investigators .  Cardiovascular 
events in patients with COPD: TORCH 
study results .  Thorax .  2010 ; 65 ( 8 ): 
719 - 725 .  
  20 .  Donohue  JF ,  Singh  D ,  Kornmann  O , 
 Lawrence  D ,  Lassen  C ,  Kramer  B .  Safety 
of indacaterol in the treatment of patients 
with COPD .  Int J Chron Obstruct Pulmon 
Dis .  2011 ; 6 : 477 - 492 .  
  21 .  Worth  H ,  Chung  KF ,  Felser  JM ,  Hu  H , 
 Rueegg  P .  Cardio- and cerebrovascular 
safety of indacaterol vs formoterol, 
salmeterol, tiotropium and placebo 
in COPD .  Respir Med .  2011 ; 105 ( 4 ):
 571 - 579 .  
  22 .  Wilchesky  M ,  Ernst  P ,  Brophy  JM ,  Platt  RW , 
 Suissa  S .  Bronchodilator use and the risk 
of arrhythmia in COPD: part 2: reassess-
ment in the larger Quebec cohort .  Chest . 
 2012 ; 142 ( 2 ): 305 - 311 . 
  23 .  Brovana (arformoterol tartrate) [package 
insert] .  Marlborough, MA :  Sunovion 
Pharmaceuticals Inc. ;  2011 . 
  24 .  Nelson  HS ,  Weiss  ST ,  Bleecker  ER , 
 Yancey  SW ,  Dorinsky  PM ;  SMART 
Study Group .  Th e Salmeterol Multicenter 
Asthma Research Trial: a comparison of 
usual pharmacotherapy for asthma or 
usual pharmacotherapy plus salmeterol . 
 Chest .  2006 ; 129 ( 1 ): 15 - 26 .  
  25 .  Donohue  JF ,  Maleki-Yazdi  MR ,  Kilbride  S , 
 Mehta  R ,  Kalberg  C ,  Church  A .  Efficacy 
and safety of once-daily umeclidinium/
 1542  Original Research  [   1 4 6  #  6   C H E S T   D E C E M B E R   2 0 1 4   ] 
vilanterol 62.5/25 mcg in COPD .  Respir 
Med .  2013 ; 107 ( 10 ): 1538 - 1546 .  
  26 .  Baumgartner  RA ,  Hanania  NA , 
 Calhoun  WJ ,  Sahn  SA ,  Sciarappa  K ,  
Hanrahan  JP .  Nebulized arformoterol in 
patients with COPD: a 12-week, multi-
center, randomized, double-blind, double-
dummy, placebo- and active-controlled 
trial .  Clin Th er .  2007 ; 29 ( 2 ): 261 - 278 .  
  27 .  Cazzola  M ,  Hanania  NA ,  Matera  MG . 
 Arformoterol tartrate in the treatment of 
COPD .  Expert Rev Respir Med .  2010 ; 4 ( 2 ): 
155 - 162 .  
  28 .  Donohue  JF ,  Hanania  NA ,  Sciarappa  KA , 
 et al .  Arformoterol and salmeterol in 
the treatment of chronic obstructive 
pulmonary disease: a one year evaluation 
of safety and tolerance .  Th er Adv Respir 
Dis .  2008 ; 2 ( 2 ): 37 - 48 .  
  29 .  Calverley  PM ,  Anderson  JA ,  Celli  B , 
 et al ;  TORCH investigators .  Salmeterol 
and fl uticasone propionate and survival 
in chronic obstructive pulmonary disease . 
 N Engl J Med .  2007 ; 356 ( 8 ): 775 - 789 .  
  30 .  Tashkin  DP ,  Celli  B ,  Senn  S ,  et al ; 
 UPLIFT Study Investigators .  A 4-year 
trial of tiotropium in chronic obstruc-
tive pulmonary disease .  N Engl J Med . 
 2008 ; 359 ( 15 ): 1543 - 1554 .  
  31 .  Welte  T ,  Miravitlles  M ,  Hernandez  P ,  
et al .  Efficacy and tolerability of 
budesonide/formoterol added to 
tiotropium in patients with chronic 
obstructive pulmonary disease .  Am J 
Respir Crit Care Med .  2009 ; 180 ( 8 ):
 741 - 750 .  
  32 .  Rabe  KF .  Treating COPD—the TORCH 
trial, P values, and the Dodo .  N Engl J 
Med .  2007 ; 356 ( 8 ): 851 - 854 .  
